If you don't remember your password, you can reset it by entering your email address and clicking the Reset Password button. You will then receive an email that contains a secure link for resetting your password
If the address matches a valid account an email will be sent to __email__ with instructions for resetting your password
Correspondence Address correspondence to: Zhi-Ren Liu, PhD, Department of Biology, Georgia State University, University Plaza, Atlanta, Georgia 30303. fax: (404) 413-5300.
Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapeutics owing to dense fibrotic stroma orchestrated by cancer-associated pancreatic stellate cells (CAPaSC). CAPaSC also support cancer cell growth, metastasis, and resistance to apoptosis. Currently, there is no effective therapy for PDAC that specifically targets CAPaSC. We previously reported a rationally designed protein, ProAgio, that targets integrin αvβ3 at a novel site and induces apoptosis in integrin αvβ3-expressing cells. Because both CAPaSC and angiogenic endothelial cells express high levels of integrin αvβ3, we aimed to analyze the effects of ProAgio in PDAC tumor.
Methods
Expression of integrin αvβ3 was examined in both patient tissue and cultured cells. The effects of ProAgio on CAPaSC were analyzed using an apoptosis assay kit. The effects of ProAgio in PDAC tumor were studied in 3 murine tumor models: subcutaneous xenograft, genetic engineered (KrasG12D; p53R172H; Pdx1-Cre, GEM-KPC) mice, and an orthotopic KrasG12D; p53R172H; Pdx1-Cre (KPC) model.
Results
ProAgio induces apoptosis in CAPaSC. ProAgio treatment significantly prolonged survival of a genetically engineered mouse–KPC and orthotopic KPC mice alone or in combination with gemcitabine (Gem). ProAgio specifically induced apoptosis in CAPaSC, resorbed collagen, and opened collapsed tumor vessels without an increase in angiogenesis in PDAC tumor, enabling drug delivery into the tumor. ProAgio decreased intratumoral insulin-like growth factor 1 levels as a result of depletion of CAPaSC and consequently decreased cytidine deaminase, a Gem metabolism enzyme in cancer cells, and thereby reduced resistance to Gem-induced apoptosis.
Conclusions
Our study suggests that ProAgio is an effective PDAC treatment agent because it specifically depletes CAPaSC and eliminates tumor angiogenesis, thereby enhancing drug delivery and Gem efficacy in PDAC tumors.
Dense stroma is a major obstacle in the treatment of pancreatic ductal adenocarcinoma. By using a de novo–designed protein agent (ProAgio) that induces cell apoptosis by targeting integrin αvβ3, we show an effective approach for pancreatic ductal adenocarcinoma treatment by simultaneously targeting cancer–associated pancreatic stellate cells and angiogenic endothelial cells.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal diseases, with a median survival of fewer than 6 months after diagnosis. Despite intensive efforts in developing effective treatments, patient survival has improved only marginally. Dense fibrotic stroma and extracellular matrix laid down by cancer-associated pancreatic stellate cells (CAPaSC) is considered to be one of the major contributors to resistance to antitumor therapies in this disease.
CAPaSC also engage in symbiotic growth factor and cytokine cross-talk with cancer cells that support tumor growth, survival, resistance to apoptosis, and metastasis.
In return, cancer cells provide factors that support PaSC proliferation and survival. Prior studies have shown that depleting cancer-associated fibroblasts (CAFs) and fibrosis can improve the efficacy of existing PDAC treatments in preclinical models.
However, recent studies of Sonic hedgehog (Shh) and α-smooth muscle actin (α-SMA) gene deletion in genetically engineered mouse (GEM) models of PDAC have suggested that some fibrotic stroma in PDAC may constitute a barrier that prevents metastatic spread of the tumor.
Integrin αvβ3 is not expressed, or is expressed at very low levels, in most normal tissues/cells. However, high levels of integrin αvβ3 often are detected in tissues at inflammatory sites, wound healing, and invasive cancers. The integrin is highly expressed in angiogenic endothelial cells and collagen-secreting myofibroblasts. Because of a lack of expression in most normal tissues/cells, it is believed that this integrin pair is an ideal and safe target for drug development for multiple pathologic conditions.
We previously reported the development of a rationally designed protein (ProAgio) that targets integrin αvβ3 at a novel site. ProAgio effectively induces apoptosis in αvβ3-expressing cells.
which prompted us to question whether activation of PaSC leads to higher expression of integrin αvβ3, thus constituting an ideal target for ProAgio. We show here that activated PaSC and CAPaSC in PDAC tumors express high levels of integrin αvβ3. By targeting integrin αvβ3, ProAgio is effective in inducing apoptosis of the activated PaSC and CAPaSC. By simultaneously targeting CAPaSC and angiogenic endothelial cells, ProAgio is effective for PDAC treatment. ProAgio depletes CAPaSC, resorbs tumor collagen, and abrogates angiogenic vessels in PDAC tumor. ProAgio treatment leads to the opening of collapsed tumor vessels, which increases tumor permeability, and facilitates drug delivery. Importantly, depletion of CAPaSC by ProAgio also reduces various growth factors and cytokines that are released from CAPaSC, and therefore breaks down the cross-talk between CAPaSC and cancer cells. As an example, ProAgio decreases insulin-like growth factor 1 (IGF1) in the tumor. A decrease in IGF1 consequently decreases cytidine deaminase (Cda) in PDAC tumor, thereby resulting in much enhanced gemcitabine efficacy in addition to an increase in the drug delivery. We conclude that specifically targeting CAPaSC by ProAgio, leaving the normal or quiescent PaSC intact, may provide an important treatment advantage.
Results
CAPaSC Express High Levels of Integrin αvβ3 and ProAgio Induces CAPaSC Apoptosis
To examine whether the integrin αvβ3 also is expressed in PaSC and CAPaSC, we first probed integrin αvβ3 levels in activated/inactivated human primary PaSC. Integrin αvβ3 is highly expressed in activated PaSC. However, inactivated PaSC expressed little to no integrin αvβ3 (Figure 1A). To evaluate the expression of integrin αvβ3 in PaSC in PDAC, we analyzed PDAC patient tumor tissues for the expression of integrin β3. We found that integrin β3 was highly up-regulated in PDAC tumor tissues. The integrin expression was particularly high in the stromal component as compared with the areas of the tumor with histologically evident adenocarcinoma. Immunostaining also showed that CAPaSC showed higher integrin β3 expression, although there was almost no integrin β3 staining in noncancerous tissues (Figure 1B). Consistently, survival analyses of PDAC patients with high and low integrin αv, integrin β3, and α-SMA expression in tumors from the KM-plotter data base
showed that integrin αvβ3 and α-SMA levels in tumor closely correlate with poor patient overall survival and relapse-free survival (Figure 1C and D), indicating the important role of integrin αvβ3-expressing cells and α-SMA–positive cells in cancer progression and patient response to treatment. ProAgio induces apoptosis in αvβ3-expressing cells.
We reasoned whether ProAgio could exert its effect on activated PaSC. Clearly, ProAgio effectively induced apoptosis in activated human primary PaSC, whereas it had a minimal effect on inactivated PaSC (Figure 1E). Similar to our previous observation,
ProAgio induced apoptosis in activated PaSC by recruiting and activating caspase 8 at the intracellular domain of the integrin β3 (Figure 1F). Our findings suggest that targeting integrin αvβ3 by ProAgio may be a unique approach that is capable of specifically depleting CAPaSC in PDAC to facilitate treatment.
Figure 1CAPaSC express integrin αvβ3. ProAgio induces CAPaSC apoptosis. (A) Levels of αV (IB, integrin αV) and β3 (IB, integrin β3) integrin in activated and inactivated human primary PaSC were analyzed by immunoblot. PaSC were activated by culturing for 48 hours in the presence of 5 ng/mL transforming growth factor (TGF)-β. Inactivated PaSC are the cells that are in day 1 culture without TGF-β. (B) (Left) Representative (tissue samples from 9 patients and a tissue array of 60 patients) images and (right) quantification of integrin β3-positive cells in stromal and adenocarcinoma (cancer cells) areas of the IHC staining of integrin β3 of PDAC patient tumor tissue samples (n = 69). (C and D) Overall survival (C) and relapse-free survival (D) of PDAC patients in the groups of high and low expression of integrin αv (ITGAV, top), integrin β3 (ITGB3, middle), and α-SMA (ACTA2, bottom) were plotted from the KM-plotter data base. ITGAV, ITGB3, and ACTA2 expression high (red line) denotes that the mRNA levels of the gene in the tumor of the patients are higher than the median value of mRNA of the gene in the entire patient group, and expression low (black line) is defined by the mRNA levels of the gene in the tumor of the patients are lower than the median value of the mRNA of the gene in the entire patient group. The number at the bottom of each panel indicates patient number. The hazard ratio (HR) and log-rank P value are indicated in each panel. (E) Apoptosis in activated PaSC (act. PaSC, red bar) or inactivated (PaSC, grey bar) PaSC after treatment with the indicated concentrations of ProAgio was measured by an apoptosis kit. Cell apoptosis is presented as the percentage of apoptosis by defining the apoptosis of untreated cells as 0%. (F) Co-immunoprecipitation of caspase 8 with integrin β3 (IP, integrin β3) in extracts of activated human primary PaSC that were treated with 5 μmol/L ProAgio for 6 hours were analyzed by immunoblots (IB, caspase 8). Immunoblot of integrin β3 (IB, integrin β3) indicates the amount of β3 precipitated down in the co-IP. Immunoblot of ProAgio (IB, ProAgio) indicates co-precipitation of ProAgio with integrin β3. (G) Mean tumor volume of subcutaneous xenograft of Panc1 with (gray line, Panc1 + CAPaSC) or without (black line, Panc1) co-implantation of PaSC. (B, E, and G) Error bars represent means ± SEM. GAPDH, glyceraldehyde-3-phosphate dehydrogenase. ∗P < .05; ∗∗P < .01; ∗∗∗P < .001; ∗∗∗∗P < .0001. co-IP, co-immunoprecipitation; IB, immunoblot; IP, immunoprecipitation; n.s., denotes not significant.
Targeting Integrin αvβ3 by ProAgio Inhibits Tumor Growth and Provides a Survival Benefit
To test the conjecture, we first examined the effects of ProAgio in mice bearing subcutaneous xenograft tumors established by co-implanting activated human PaSC with human Panc1 cells. Co-implantation with human PaSC significantly promoted tumor growth (Figure 1G). ProAgio inhibited Panc-1 tumor growth without PaSC co-implant, although the inhibitory effects were greater when Panc1 was co-implanted with human PaSC (Figure 2A). Consistently, tumors in mice in the ProAgio treatment group weighed less at the end of the experiment compared with the vehicle group (Figure 2B). Upon activation, PaSC attain a myofibroblast-like phenotype, up-regulating α-SMA and integrin αvβ3, and secrete collagen. Because ProAgio effectively induced apoptosis in activated PaSC, we reasoned whether ProAgio would exert its effects in vivo on co-implanted PaSC, and thus on the collagen secreted by the PaSC. Immunostain showed that α-SMA–positive cells were reduced with much higher reduction in the PaSC co-implanted tumors (Figure 2C and D), and Masson trichrome stain showed a decrease in intratumoral collagen content after ProAgio treatment (Figure 2E and F). The co-implanted PaSC facilitated Panc1 proliferation in tumor as shown by increased Ki67 staining. ProAgio abrogated the effects of tumor proliferation promoted by PaSC (Figure 2G and H). Similar to our previous observation, ProAgio treatment decreased the tumor vasculature (Figure 2I and J).
Figure 2ProAgio depletes CAPaSC by targeting integrin αVβ3and resorbs tumor collagen. (A and B) Mean tumor volume of (A) subcutaneous xenograft of Panc1 with (solid lines) or without (dotted lines) co-implantation of PaSC and mean tumor weight (B) of Panc1 subcutaneous xenograft with or without co-implantation of PaSC upon treatment with vehicle (black lines in panel A, grey dots in panel B) or 10 mg/kg ProAgio (12 daily doses, red lines in panel A, red dots in panel B) (n = 6). (C and E) Representative images of immunofluorescence staining of α-SMA (red) (C) and Masson trichrome (blue) staining for collagen (E). (D and F) Quantitative analyses of immunofluorescence staining of α-SMA (D) and Masson trichrome (F) staining in tumor sections of Panc1 xenograft (with or without PaSC co-implantation) mice treated with vehicle or 10 mg/kg ProAgio. (G and I) Representative images of immunofluorescence staining of Ki67 (G, red) and CD31 (I, red). (H and J) Quantitative analyses of immunofluorescence staining of Ki67 (H) and quantification of mean vessel density, branch points, and vessel length based on CD31 staining (J) in tumor sections of Panc1 xenograft (with or without PaSC co-implantation) mice treated with vehicle or ProAgio. Quantification of Ki67 staining is presented as the percentage of Ki67+ nuclei per view field (upper 3 panels, with PaSC co-implantation; bottom 3 panels, without PaSC co-implantation). (C, G, and I) Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). (A and B) Error bars represent means ± SEM. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001. n.s., denotes not significant.
It is noteworthy that the Panc1 subcutaneous xenograft model does not recapitulate some important properties of patient PDAC tumors, especially the dense fibrotic stroma and the collapsed intratumoral vessels. To accurately evaluate the effects of depletion of CAPaSC by ProAgio on PDAC, we used a GEM model: Lox-Stop-Lox (LSL)-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) (referred to as GEM-KPC)
(Figure 3A and B). The ProAgio single agent modestly prolonged GEM-KPC mice survival (Figure 3C). An orthotopic model of PDAC is another model system that well-mimics the patient PDAC tumor microenvironment. In addition, owing to rapid growth of the tumor,
the orthotopic model is excellent to test the treatment effects of drug on PDAC. Thus, the effectiveness of ProAgio on PDAC also was tested in mice bearing orthotopic tumors derived from cells isolated from the tumor of KPC mice (KPC 961 cell line,
Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
referred to as OrKPC hereafter). ProAgio provided significant survival benefit compared with vehicle (Figure 3D). Analyses of tumor sections from GEM-KPC and OrKPC mice at the end of the survival experiment or immediately after 20 doses of ProAgio treatment showed a significant reduction in the levels of fibrosis, as shown by reduced intratumoral collagen content (Figure 3E, F, and H), and levels of α-SMA–positive fibroblasts (Figure 3E, G, and H). In consistence, messenger RNA (mRNA) levels of α-SMA and Fibroblast activation protein (FAP) measured by quantitative reverse-transcription polymerase chain reaction were reduced significantly in the tumor lysates of GEM-KPC mice upon treatment with ProAgio (Figure 3I), suggesting a reduction in CAPaSC by ProAgio in the tumor. We previously showed that ProAgio shows anti-angiogenic activity resulting from induction of apoptosis in angiogenic endothelial cells.
We therefore analyzed the effects of ProAgio on tumor vessels in the treated GEM-KPC and OrKPC tumors. Unlike previous observations that depletion of cancer-associated fibroblasts by genetically depleting the Shh gene promotes tumor angiogenesis,
depletion of CAPaSC by ProAgio did not result in an increase of vessel density in both GEM-KPC and OrKPC tumors (Figure 4A, B, E, and F). However, ProAgio treatment showed a profound effect on the tumor vasculature because the majority of intratumoral vessels were noted to be prominently open and, when measured, the mean vessel luminal area was increased significantly (Figure 4A, C, E, and G). A similar phenomenon also was observed and reported by Olive et al.
This is presumably owing to relief of high intratumoral pressure because of depleted rigid and dense collagen fibrils.
Figure 3ProAgio depletes CAPaSC by targeting integrin αVβ3and resorbs tumor collagen. (A) Endogenous alleles of KrasG12D and Trp53R172H are conditionally activated in the pancreata of LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (triple mutant) mice. (B) Specific polymerase chain reaction analysis of genomic DNA of generated GEM-KPC mice. (C and D) Kaplan–Meier survival analysis of GEM-KPC (median survival: vehicle, 20 days; ProAgio, 51 days) (A), and OrKPC (B) mice treated with vehicle or 10 mg/kg ProAgio (median survival: vehicle, 31 days; ProAgio, 39 days) (10 daily doses + 10 alternate day doses). Treatment was started after 13 weeks of age in GEM-KPC mice in panel C, or 30 days after tumor inoculation in panel D. The numbers in parentheses indicate the group size. (E) Representative images of Sirius red (red) and Masson trichrome (blue) staining and IHC staining of α-SMA of tumor sections from GEM-KPC mice treated with vehicle or 10 mg/kg ProAgio at different time points (Rx 20, at end of 20 doses; End stage, end of survival experiments). (F and G) Quantitative analyses of Sirius red staining (presented as Sirius red+ area %) (F) and αSMA+ staining area % (G) in tumor sections of vehicle or ProAgio-treated (10 mg/kg) GEM-KPC mice. A higher staining of Sirius red was observed in vehicle-treated tumors on day 80 (Rx 20 doses) than ProAgio-treated tumors on day 110 (end stage) in GEM-KPC mice (P < .001; n = 7–9). (H) Representative images of Sirius red (Sirius red) and IHC staining of α-SMA in tumor sections of vehicle or ProAgio-treated (10 mg/kg) OrKPC mice at the end of 20 doses (Rx 20 doses). (I) mRNA levels of α-SMA (left panel) and FAP (right panel) in the tumor tissue lysates of GEM-KPC mice treated with vehicle or ProAgio (n = 4) were analyzed by quantitative reverse-transcription polymerase chain reaction. The mRNA levels in the tumor extracts were normalized to mRNA level of β-actin. (G) Error bars represent means ± SEM. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001. n.s., denotes not significant; WT, wild-type.
Figure 4ProAgio opens compressed tumor vessels and increases drug delivery. (A) Representative images of IHC staining of CD31 from GEM-KPC mice tumor sections treated with vehicle or 10 mg/kg ProAgio. Arrows indicate example vessels. (B and C) Quantification of CD31-positive vessel density (B), and mean vessel lumen area (C) in tumor sections of vehicle or ProAgio-treated GEM-KPC mice. (D) Intratumoral Gem levels measured in extracts of tumors of vehicle and ProAgio-treated (after 8 daily doses) GEM-KPC mice 2 hours after intravenous dose of Gem (n = 6). Gem levels were presented as nanogram of Gem per milligram of tumor tissue. (E) Representative images of IHC staining of CD31 in tumor sections of vehicle or ProAgio-treated OrKPC mice. Arrows indicate the tumor vessels. (F and G) Quantitative analyses of CD31 vessel stain density (F) and vessel lumen area (G) in tumor sections of vehicle or ProAgio-treated OrKPC mice. (H and I) Representative fluorescence images of Alexa Fluor 555–conjugated IgG, approximately 160 kilodalton (red) and Alexa Fluor 488–conjugated paclitaxel, approximately 1 kilodalton (green; left panel, 10×; right panel, 30×) (H) and quantification of fluorescence signals from paclitaxel and IgG (I) in tumor sections of vehicle or ProAgio-treated OrKPC mice using ImageJ. (J–L) Representative fluorescence images of Alexa Fluor 555–conjugated IgG, approximately 160 kilodalton (red) and Alexa Fluor 488–conjugated paclitaxel, approximately 1 kilodalton (green) (J) and quantification of fluorescence signals (K and L) in tumor sections of OrKPC mice treated with the indicated agents. Quantification is presented as fold change of the fluorescence integrated density (fold) by comparing it with the mean value of the vehicle treatment group as 1. Image analysis was performed by thresholding for positive staining and normalizing to total tissue area. (H and I) Fluorescence probe conjugated IgG and paclitaxel were injected intravenously after 8 daily doses of 10 mg/kg ProAgio treatment. (J–L) Fluorescence probe–conjugated IgG and paclitaxel were injected intravenously after 8 daily doses of ProAgio (ProAgio), 3 doses of Gem (Gem), or 8 doses of ProAgio plus 3 doses of Gem (ProAgio + Gem) treatments. Tumors were harvested and processed 40 minutes after the intravenous injection (analyses: n = 5 mice per treatment group, n = 7–8 images per mouse). Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue), and yellow indicates colocalization. (D, I, K, and L) Error bars represent means ± SEM. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001. n.s., denotes not significant.
Depletion of CAPaSC by ProAgio Increases Intratumoral Drug Delivery
One of the major reasons for chemoresistance in PDAC is the impediment of drug delivery owing to the presence of dense collagen fibrils that physically block drug distribution inside the tumor and the completely collapsed intratumoral blood vessels that lead to poor blood perfusion.
ProAgio reduced tumor collagen and opened the intratumoral vessels without an increase in angiogenesis. We therefore believed that ProAgio could eliminate both drug delivery barriers and thereby facilitate the delivery of chemotherapeutic agents to tumor. To evaluate the effects of ProAgio on drug delivery, GEM-KPC mice were treated with 8 daily doses of ProAgio, followed by 1 intravenous dose of gemcitabine (Gem). Tumor lysates subsequently were analyzed. ProAgio treatment resulted in a more than 2.5-fold increase in intratumoral Gem delivery (Figure 4D). A similar increase also was observed in ProAgio-treated OrKPC mice upon intravenous administration of fluorescent probe–conjugated molecules (paclitaxel and IgG) after 8 daily doses of ProAgio (Figure 4H and I).
A strong increase in drug molecule intratumoral delivery predicts the treatment efficacy of ProAgio in combination with other anticancer drugs. We performed treatment using ProAgio in combination with Gem (50 mg/kg intraperitoneally twice weekly) in both GEM-KPC and OrKPC models. The treatment started at a late stage of cancer development (Figure 5A and B). In the GEM-KPC model, Gem alone provided a marginal survival benefit, ProAgio alone provided a modest survival benefit, and ProAgio combined with Gem dramatically prolonged GEM-KPC mice survival (Figure 5C). Similar results were observed in the OrKPC model (Figure 5D). An increase in apoptosis in the stromal area was observed in the ProAgio group, although this increase was not observed in the Gem group (Figure 5F). ProAgio alone did not lead to a substantial increase in apoptosis in areas of histologically evident adenocarcinoma in the tumor. A more than 3-fold increase in apoptosis in the adenocarcinoma area was observed in the ProAgio and Gem combination group compared with the ProAgio alone group (Figure 5G), suggesting that ProAgio induced apoptosis in stromal fibroblasts, although it had less effects on PDAC cancer cells. In case of the combination, ProAgio increased the delivery of Gem, which led to cancer cell apoptosis. The observation was consistent with in vitro tests with PDAC cancer cells and PaSC (Figure 5H). In addition, the combination of ProAgio and Gem did not have an additive effect on cultured pancreatic cancer cells (Figure 5I). We measured the collagen content and levels of α-SMA–positive cells in the treated tumors. Both ProAgio and ProAgio plus Gem reduced intratumoral collagen content and α-SMA–positive cells in GEM-KPC (Figure 6A–C and E) and OrKPC tumors (Figure 6A, B, D, and F). Because of a reduction in intratumoral collagen, ProAgio and ProAgio plus Gem treatments resulted in reduced tumor weight (Figure 5E). We again analyzed delivery of the fluorescence probe–conjugated paclitaxel and IgG to the tumors under ProAgio and ProAgio plus Gem. Interestingly, the ProAgio plus Gem combination further increased the drug molecule delivery dramatically (Figure 4J–L) compared with ProAgio alone. Although we do not understand the molecular mechanism by which ProAgio plus Gem further increases tumor permeability, such a drastic increase in intratumoral delivery of drug molecule would confer a good treatment benefit.
Figure 5Depletion of CAPaSC by ProAgio enhances the effectiveness of gemcitabine. (A and B) The 10 mg/kg ProAgio and 50 mg/kg Gem treatment regimen of GEM-KPC (A) and OrKPC (B) mice. (C and D) Kaplan–Meier survival analyses of GEM-KPC (median survival: vehicle, 12 days; Gem, 34.5 days; ProAgio, 49 days; ProAgio + Gem, 155 days) (C), and OrKPC (median survival: vehicle, 31 days; Gem, 28 days; ProAgio, 39 days; ProAgio + Gem, 58 days) (D) mice upon indicated treatments. The numbers in the parentheses are the group size. (E) Mean tumor weight of OrKPC mice (n = 7) treated with the indicated agents at the end of treatment (mice were killed at the end of the treatment and tumors were resected and weighed). (F and G) Quantification of IHC staining of cleaved caspase 3 in stromal areas (stromal CC3+ cells/high-power field [HPF], cleaved caspase 3–positive cells per view field) (F) and adenocarcinoma area (epithelial CC3+ cells/HPF) (G) in tumor sections from GEM-KPC mice upon indicated treatments. (H) Cell viability of indicated cells upon treatment with ProAgio (5 μmol/L) and Gem (1 mmol/L) was analyzed by MTT assay. (I) The cell viability of KPC 961 cells treated with ProAgio, Gem, and ProAgio plus Gem combination was analyzed by MTT assay. (H and I) The viability of vehicle-treated cells (control) was defined as 100%. (E, H, and I) Error bars represent means ± SEM. MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Figure 6ProAgio plus Gem further reduces intratumoral collagen and CAPaSC. (A and B) Representative images of Sirius red staining (A) and IHC staining of α-SMA (B) in tumor sections from GEM-KPC and OrKPC mice treated with the indicated agents. (C–F) Quantitative analyses of Sirius red stain area (Sirius red+ area %) (C and D) and IHC α-SMA stain area (α-SMA+ area %) (E and F) in sections of tumors from GEM-KPC and OrKPC mice treated by the indicated agents. (F) Error bars represent means ± SEM. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001. n.s., not significant.
Depletion of CAPaSC by ProAgio Enhances Gem Efficacy by Altering Gem Metabolism
ProAgio plus Gem offers a strong survival benefit over Gem or ProAgio alone. We sought to elucidate the mechanism(s) that may contribute to such strongly enhanced antitumor activity of the combination therapy. We examined the intratumoral levels of the Gem prodrug 2′,2′-difluorodeoxcytidine (dFdC) and the inactivated and activated metabolites (2′,2′-difluorodeoxyuridine [dFdU] and gemcitabine triphosphate [dFdCTP]).
We found that the combination led to a higher dFdC:dFdU ratio and an increased amount of dFdCTP (active drug form) in tumors (Figure 7A and B). Thus, in addition to increased Gem delivery, ProAgio also increased the active drug form of Gem (dFdC) and decreased the inactive derivative (dFdU). We therefore asked how ProAgio prevented the conversion of Gem to its inactive metabolite. One mechanism by which PDAC becomes resistant to Gem is the conversion of Gem to dFdU by up-regulation of Cda.
Therefore, we histologically examined the enzyme Cda in tumors of ProAgio-treated mice. Cda is expressed primarily in the carcinoma cells. ProAgio and the combination decreased Cda expression in GEM-KPC and OrKPC tumors (Figure 7C and D). Immunoblot of tumor extracts confirmed the decrease in Cda in GEM-KPC tumors upon ProAgio treatment (Figure 7E). Gem is a prodrug form of dFdCTP. It needs to be converted to Gemcitabine monophosphate by an enzyme named deoxycytidine kinase (Dck). Pyrimidine kinase Thymidine kinase (Tdk) also is capable of increasing dFdCTP from Gem.
Thus, we examined whether an increase in dFdCTP under ProAgio treatment was owing to an increase in Dck and/or Tdk. Clearly, ProAgio did not alter Dck or Tdk in the tumor (Figure 7F–I). ProAgio also did not change the expression of multidrug resistance–associated protein 1 (ABCC1) (Figure 7J), another important player involved in cancer cell resistance to Gem.
Examination of IGF1R phosphorylation and Cda levels in PDAC patient tissue samples showed a close correlation (Figure 8A and B), suggesting a possible role of IGF1R in regulating Cda in pancreatic cancer. The addition of IGF1 to the culture of KPC 961 cells up-regulated Cda expression in the cells (Figure 8C), verifying the role of IGF1 in up-regulation of Cda in this PDAC cell line. IGF1 is a common growth hormone, produced mainly by the liver in a healthy individual.
Furthermore, high insulin levels in pancreas may up-regulate IGF1 expression and activate Insulin-like growth factor 1 receptor (IGF1R signaling in PDAC tumor.
Because ProAgio depletes CAPaSC, we questioned whether ProAgio reduced IGF1 in PDAC, and thus consequentially suppressed Cda expression. We first examined the secretion of IGF1 by quiescent PaSC vs activated PaSC, and pancreatic cancer cells vs activated PaSC. Clearly, activated PaSC secrete higher levels of IGF1 than quiescent PaSC (Figure 8D). We also found that activated PaSC secrete higher levels of IGF1 than pancreatic cancer cells (Figure 8E). Furthermore, xenograft tumors of Panc1 co-implanted with PaSC secrete higher levels of IGF1 than the tumor without co-implantation (Figure 8F). We then examined the IGF1 levels in tumors of ProAgio and the combination treated GEM-KPC mice. Evidently, ProAgio and the combination led to a reduced IGF1 in GEM-KPC tumors (Figure 8G and H). In addition, the effect of ProAgio on IGF1 secretion was significantly higher in co-implanted tumors than without co-implantation in the Panc1 xenograft mouse model (Figure 8F). Our results support that ProAgio mediates reduced IGF1 levels in the tumor by CAPaSC depletion. ProAgio also led to a reduction in IGF1R phosphorylation in the tumors (Figure 8I and J). Consistently, in the presence of IGF1, KPC 961 cells were less susceptible to apoptosis induction by Gem (Figure 8K), and knockdown of Cda conferred KPC 961 cells more sensitive to apoptosis induction by Gem (Figure 8L and M).
Figure 7Depletion of CAPaSC by ProAgio alters Gem metabolism and reduces cancer cell resistance to Gem. (A and B) Intratumoral levels of dFdCTP (A) and the dFdC:dFdU ratio (B) in tumor tissues of GEM-KPC mice treated with the indicated agents measured by high-performance liquid chromatography/mass spectrometry. The concentration of dFdCTP, dFdC, and dFdU in tumor tissues was analyzed 2 hours after the last dose of Gem (n = 6). (C and D) Representative images of IHC staining of Cda (C) and quantitation of IHC staining of Cda (D) (Cda+ area [fold], fold change by comparison with the mean value of the ProAgio group as 1) in tumor sections of GEM-KPC and OrKPC mice treated with the indicated agents. (E) The levels of Cda (IB:Cda) in tumor extracts of vehicle or ProAgio-treated GEM-KPC mice were analyzed by immunoblot. Immunoblot of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (IB:GAPDH) is a loading control. (F and H) Representative images of IHC staining of Tdk (F) and Dck (H), and (G and I) quantitative analyses of Tdk-positive stain area (G) and Dck-positive stain area (I) in tumor sections of ProAgio-treated GEM-KPC mice. (J) The mRNA levels of Cda, Dck, Tdk, and ABCC1 genes in the tumor extracts of the indicated treatment cohorts (n = 6) were analyzed by quantitative reverse-transcription polymerase chain reaction. The mRNA levels in the tumor extracts were normalized to the mRNA level of GAPDH. (A) Error bars represent means ± SEM. IB, immunoblot.
Figure 8ProAgio decreases Cda in cancer cells by decreasing IGF1 signaling. (A) Representative images of IHC staining of pIGF1R (left panel; 4× and 10× enlarged images) and Cda (right panel, 4× and 10× enlarged images) in tumor sections of PDAC patients (n = 40). (B) Correlation of pIGF1R protein expression with Cda protein expression. Regression analysis for expression of the pIGF1R (IHC) vs Cda (IHC) in tumor sections of PDAC patients (n = 12). (C) The levels of Cda (IB:Cda) in KPC 961 cells that were treated with IGF-1 (0 ng/mL and 10 ng/mL) were analyzed by immunoblot. (D) Levels of IGF1 secreted by inactivated PaSC (without transforming growth factor [TGF]-β, grey bar) or activated PaSC (with 5 ng/mL TGF-β, black bar). (E) Levels of IGF1 secreted by the indicated cells. (F) Levels of IGF1 in the serum of a subcutaneous xenograft mouse model of Panc1 or Panc1 co-implanted with activated human PaSC treated with vehicle or ProAgio (n = 5). IGF1 levels were analyzed by enzyme-linked immunosorbent assay. (G and H) Representative images of IHC staining of IGF1 (G) and quantitation of IHC staining of IGF1 (H) (IGF1+ area [X], fold change by comparison with the mean value of the ProAgio group as 1) in tumor sections of GEM-KPC mice treated with the indicated agents. (I and J) Representative images of IHC staining of pIGF1R (I) and quantitation of pIGF1R-positive staining (J, pIGFR+ cells/HPF, pIGFR-positive cells per view field) in tumor sections of vehicle or ProAgio-treated OrKPC mice. (K) Apoptosis of KPC 961 cells after treatment with Gem (1 μmol/L, grey bar, or 1 mmol/L, black bar) in the presence (+IGF1) or absence (-IGF1) of 10 ng/mL IGF1 was measured by an apoptosis kit. Cell apoptosis is presented as the percentage of apoptosis by defining the apoptosis of untreated cells as 0%. (L) The levels of Cda (IB:Cda) in KPC 961 cells after Cda knockdown (Cda small interfering RNA [siRNA]) compared with control (ctrl siRNA) were analyzed by immunoblot. (M) Cell viability of KPC 961 cells with (Cda siRNA) or without (ctrl siRNA) knockdown of Cda treated with the indicated concentrations of Gem was measured by MTT assay. (C and L) Immunoblot of β-actin (IB:β-actin) is a loading control. (D, E, F, K, and M) Error bars represent means ± SEM. MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; pIGF1R, Phospho-IGF-I Receptor; X, times.
Depletion of CAPaSC by ProAgio Decreases Hypoxia in PDAC Tumor
ProAgio and ProAgio plus Gem offered a very important advantage in PDAC treatment because a substantial decrease in metastasis was observed in GEM-KPC mice (Figure 9A–C). A reduction in metastasis potentially has a critical impact on PDAC patient survival. Because ProAgio did not affect the pancreatic cancer cells, we wondered how ProAgio reduced PDAC metastasis. ProAgio reduced dense collagen bundles in the tumor, which disrupted the superhighway for PDAC cancer cell migration, and thus metastasis. In addition, ProAgio opened the collapsed blood vessels in PDAC tumor (Figure 4A–E), which would decrease hypoxia in tumor. Indeed, ProAgio decreased Hypoxia-inducible factor 1-alpha levels in the treated tumors (Figure 9D and E). Hypoxia is known to up-regulate and activate IGF1R.
ProAgio decreased IGF1 owing to depletion of CAPaSC in the tumor. ProAgio also decreased hypoxia. We therefore believe that the effect of ProAgio on IGF1R signaling, in addition to reducing cancer cell apoptosis resistance,
also might play a role in PDAC metastasis. Cell migration assay showed that IGF1 stimulated cell migration under hypoxia condition, while IGF1 had limited effects on cell migration under normoxic conditions. The effect of IGF1 on cell migration was dose-dependent because IGF1 had no effect on migration at a concentration as low as 1 ng/mL (Figure 9F–I).
Figure 9Depletion of CAPaSC by ProAgio decreases metastasis and poorly differentiated tumors. (A) Representative images of H&E staining of liver tissue sections of GEM-KPC mice treated with the indicated agents. Liver metastasis lesions were confirmed under the microscope and marked by a black dotted circle in the images. (B and C) Percentage of GEM-KPC mice treated with vehicle or 10 mg/kg ProAgio that show a different number of liver metastatic nodules (>5, >5 nodules; 1–5, 1–5 nodules; 0, no metastatic nodule) (B); and the number of metastatic nodules in the liver of GEM-KPC mice treated with vehicle or ProAgio (C). Metastatic nodules were assessed by gross inspection of the liver of each treated mouse by naked eye or under the microscope. (D and E) Representative images of IHC staining of Hif-1α (D), and quantitative analyses of Hif-1α stain (E, Hif-1α+ area [fold], fold change by comparison with the mean value of the ProAgio group as 1) in tumor sections of GEM-KPC mice treated with vehicle or ProAgio. (F and G) In vitro scratch wound healing assay of KPC 961 cells cultured under hypoxia and untreated (left) or treated with IGF1 (right) compared with those cultured under normoxia as a control (F) and quantitative analyses of the migrating cells in the scratched areas (G). (H and I) The scratch wound healing assay of KPC 961 cells cultured under hypoxia and treated with the indicated concentrations of IGF1 for the indicated amounts of time, compared with those cultured under normoxia as a control (H) and quantitative analyses of the migrating cells in the scratched areas after IGF1 treatment (I). (G and I) Error bars represent means ± SEM. ∗P < .05, ∗∗P < .01, ∗∗∗P < .001, ∗∗∗∗P < .0001. Hif, hypoxia-inducible factor; n.s., denotes not significant.
Effects of Specific Targeting of CAPaSC by ProAgio
Despite the known protumorigenic properties of CAF, recent studies have suggested that depletion of fibrotic stroma has the potential to accelerate the disease and lead to cancer progression.
To assess how CAPaSC depletion by ProAgio affects the differentiation and aggressiveness of PDAC tumors, we analyzed tumor tissue from GEM-KPC mice at the end of the survival experiment. In concert with longer survival, tumors from ProAgio-treated GEM-KPC mice were more differentiated and had a decreased pathologic disease progression compared with vehicle-treated mice (Figure 10A and B). We analyzed the proliferation marker Ki67 in vehicle- and ProAgio-treated mice and found that ProAgio-treated mice had decreased cell proliferation (Figure 10C and D). ProAgio also significantly decreased tumor metastases to the liver (Figure 9A–C). We asked why targeting fibrotic stroma by ProAgio did not result in more poorly differentiated and aggressive tumor as observed by other strategies that target fibrotic stroma.
The important difference is that ProAgio induces apoptosis via targeting integrin αvβ3. In PDAC, only CAPaSC are integrin αvβ3 positive, while inactivated PaSC are αvβ3 negative. ProAgio only depletes the CAPaSC, leaving the normal or quiescent PaSC intact. To verify this unique targeting property, we examined the status and levels of PaSC by retinol staining (retinol stains inactivated PaSC) in the treated GEM-KPC tumors. Clearly, there was almost no inactivated PaSC in vehicle-treated tumors. However, the inactivated PaSC levels were higher in tumors of ProAgio plus Gem–treated animals (Figure 10E and F). Furthermore, we stained the tumor sections with adipophilin, a marker for quiescent PaSC,
and cleaved Poly (ADP-ribose) polymerase (PARP), an apoptosis marker. Consistent with retinol staining, there was less adipophilin stain in the sections of vehicle-treated animals. ProAgio led to an approximately 2-fold, and ProAgio plus Gem led to more than a 6-fold, increase in adipophilin staining compared with those of the vehicle-treated group (Figure 10G and H). There was almost no adipophilin and cleaved PARP co-stain in any case. Thus, both in vitro and in vivo studies have suggested that ProAgio specifically induces CAPaSC apoptosis. We do not fully understand the mechanism by which ProAgio and ProAgio plus Gem lead to an increase in inactivated/quiescent PaSC in tumor. It is possible that the treatments, especially the combination, removed cancer cells. Thus, PaSC activation by cancer cells is reduced. The explanation is consistent with the fact that the increase in inactivated PaSC in the ProAgio plus Gem group is higher than in the ProAgio alone group.
Figure 10Targeting integrin αvβ3specifically depletes CAPaSC in tumor. (A and B) Representative images of H&E staining (A) and pathologic assessment (B) of the tumors of GEM-KPC mice treated with vehicle or ProAgio. (C and D) Representative images of IHC staining of Ki67 (C), and quantitative analyses of Ki67-positive stain area (D) in tumor sections of vehicle or ProAgio-treated GEM-KPC mice. (E and F) Representative images of Oil red O staining (E) and quantitative analysis of Oil red O staining (F, Oil red+ area [fold], fold change by comparison with the mean value of the vehicle-treated group as 1) in tumor sections of GEM-KPC mice treated with the indicated agents (n = 4). (G and H) Representative images of co-staining of adipophilin (green) and cleaved PARP (red) (G), and quantification of adipophilin stain (H, adipophilin+ area [fold], fold change by comparison with the mean value of the vehicle treatment group as 1) in tumor sections of GEM-KPC treated with the indicated agents using ImageJ (n = 5). Image analysis was performed by thresholding for positive staining and normalizing to the total tissue area. Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). (I) Schematic illustration of the mechanism depicting the action of ProAgio in PDAC tumor. (B, F, and H) Error bars represent means ± SEM. PARP, Poly (ADP-ribose) polymerase.
We show here that targeting integrin αvβ3 by ProAgio specifically induces apoptosis of CAPaSC. CAPaSC are the major source of collagen secretion in PDAC tumor. On the other hand, there are numerous sources (cancer cells, immune cells) for Matrix metalloproteinases secretion, which can digest collagen. Thus, ProAgio enables reduction of stromal collagen in the tumor. Reduction of collagen consequently opened the collapsed tumor vessels. Removal of a physical block by depletion of dense collagen and opening of collapsed vessels resulted in increased delivery of drug molecules into the tumor. Induction of apoptosis of CAPaSC by ProAgio also remarkably reduced IGF1, and possible other growth factors and cytokines, which is produced mainly by CAF in cancerous tissue, and consequently resulted in a decrease and inactivation of IGF1R in cancer cells. A decrease and inactivation of IGF1R suppressed Cda expression, which stabilized Gem in cancer cells equivalent to an increase in active Gem concentration in cancer cells. Moreover, opening the collapsed blood vessels reduced hypoxia. A reduction in hypoxia in conjunction with decreased IGF1 and inactivation of IGF1R decreased cancer cell migration, thereby decreasing cancer metastasis. Thus, it is clear that ProAgio enacts multiple effects on PDAC by specifically acting on CAPaSC and angiogenic endothelial cells (Figure 10I).
It generally is believed that dense fibrotic stroma is a major obstacle for successful treatment of PDAC. CAF supports cancer cell growth, survival, resistance to apoptosis, and metastasis. Thus, it is speculated that depletion of fibrotic stroma would be therapeutically advantageous in PDAC. However, recent studies of Shh and α-SMA gene deletion in PDAC GEM models suggest that some fibrotic stroma in PDAC may constitute a barrier that prevents metastatic spread of the tumor.
It should be noted that Shh or α-SMA gene deletion leads to global deletion of fibroblasts, resulting in downstream effects in excess of what would be expected from a tumor-targeted therapeutic. Pharmacologic inhibition of Shh signaling also may impose effects far beyond fibroblasts. Importantly, unlike globally targeting fibroblasts, specifically acting on CAF by ProAgio may confer an advantage in cancer therapy. Indeed, ProAgio treatment did not lead to more aggressive cancer with increased metastasis and did not increase angiogenesis in the tumor as observed with Shh or α-SMA gene deletion or Shh inhibition. A recent large-scale patient tumor study showed that the percentage of stromal cells determines the phenotypic nature of PDAC, wherein an increase in stromal cells leads to high proliferative and high migratory phenotype. The effectiveness of ProAgio in PDAC treatment provides a good explanation for the observation because ProAgio specifically depletes CAPaSC, leading to a decrease in PDAC cancer cell proliferation and migration.
One main advantage of targeting integrin αvβ3 by ProAgio is the decrease in PDAC metastasis upon ProAgio treatment (Figure 9A–C). Our experiments showed that ProAgio affects the metastasis of tumor cells by the following mechanisms: (1) ProAgio depletes CAPaSC, which encourages tumor cell metastasis; (2) ProAgio decreases collagen, which provides a superhighway for tumor cell migration–metastasis; (3) ProAgio opens collapsed PDAC blood vessels, which decreases tumor hypoxia, and a decrease in tumor hypoxia reduces tumor cell metastasis; and (4) IGF1 promotes the migration of KPC cells, particularly under hypoxia conditions. ProAgio reduces IGF1 levels in the tumor by depleting CAPaSC and therefore reduces metastasis.
Enzymatic inactivation of gemcitabine is the main reason leading to cancer resistance to this anticancer drug. Intriguingly, ProAgio decreases IGF1 by depleting CAPaSC, which consequently suppresses Cda expression in cancer cells. Our data clearly show that activated PaSC have significantly higher IGF1 secretion compared with the quiescent PaSC and pancreatic cancer cells (Figure 8D and E). IGF1 secretion is higher in Panc1 tumors co-implanted with PaSC compared with tumor without co-implantation (Figure 8F). Furthermore, ProAgio had greater effects on IGF1 secretion in Panc1 tumors with PaSC co-implantation (Figure 8F). The results suggest that ProAgio mediates reduced IGF1 levels by CAPaSC depletion. It recently was shown that CAPaSC also traps Gem in the cancer stroma.
Depletion of CAPaSC by ProAgio would release the trapped Gem and increase available Gem to cancer cells. Because Gem has been approved for the treatment of multiple different cancer types,
it will be interesting to test whether the same mechanism will be true for the Gem treatment resistance in other cancers.
Materials and Methods
Primary Human Pancreatic Stellate Cells and Activation
Primary human pancreatic stellate cells were purchased from Cell Biologics (Chicago, IL). The cells were cultured according to the manufacturer’s instructions. PaSC were activated by culturing them for 48 hours in the presence of 5 ng/mL transforming growth factor-β.
Panc1 Xenograft, GEM-KPC, and OrKPC Mice Generation and Treatments, and Patient Tissue Sample Screening
All animal experiments were performed under approval of the Institutional Animal Care and Use Committee of Georgia State University.
Panc1 xenograft
Panc1 (1 × 106) cells with/without (1:1 ratio) activated human PaSC (1 × 106) were implanted into the right flank of nude mice. Tumor growth was measured using a caliper ruler.
GEM-KPC
LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre mice were purchased from Jackson Laboratory (Bar Harbor, ME). GEM-KPC mice were generated by crossing LSL-KrasG12D/+ with LSL-Trp53R172H/+, and subsequently crossing with Pdx-1-Cre.
OrKPC
First, C57BL/6J mice were anesthetized. The pancreas was exposed through an abdominal incision. A single-cell suspension of 0.5 × 105 KPC 961 cells in 50 μL Hank’s balanced salt solution was injected directly into the pancreas using a 30G needle. After injection, the mice without leakage during injection were included in the experiments. After inoculation, the pancreas was returned carefully to the peritoneal cavity and the abdomen was closed. After tumor implantation, all mice were returned to their cages and monitored daily. GEM-KPC mice treatments were started at 14 weeks of age. For OrKPC mice, treatments were started approximately 30 days after tumor inoculation. Mice were enrolled in treatment groups randomly and palpated twice a week for evidence of tumor after group division. A portion of each group of mice were examined by ultrasound imaging to confirm the evidence of tumor presence. At the end of the treatments, animals either were killed for analyses or maintained in the cages for survival assessment. Organs, tumor tissues, and blood samples were collected at the end of the experiments for subsequent analyses. For all treatments, the vehicle administered was ProAgio formulation buffer in which ProAgio is dissolved, the ProAgio dose was 10 mg/kg, and Gem was 50 mg/kg via intraperitoneal injection. A 10-mg/kg dose was chosen based on our previous dose response in the in vivo analyses.
The treatment schedule is specified in figures or legends. Statistical analyses were performed in comparison with the control group.
Patient tissue analyses were performed in accordance with the National Institutes of Health guidelines. All tissue samples are de-identified, which falls under Institutional Review Board exemption 4. Tissue samples were sectioned and analyzed by immunohistochemical (IHC) staining. Samples were obtained either from commercial sources or the Emory-Winship Cancer Center patient tissue bank.
Tissue Section Staining
Sirius red, Masson trichrome, and Oil red O staining were performed using kits obtained from IHC WORLD (Woodstock, MD) by following the vendor’s instructions.
IHC and immunofluorescence
The IHC and immunofluorescence staining procedures were similar to those of previous reports.
Images were captured at various magnification lens apertures and indicated by scale bars in the images.
Quantitation of Sirius red, Masson trichrome, Oil red O, IHC, and immunofluorescence staining was performed using ImageJ software (National Institutes of Health, Bethesda, MD). Quantities are presented as the percentage of positive stain area in each view field or fold change by comparison with the control (vehicle) unless otherwise specified in the figures and legends. All quantitation results were means of 3 randomly selected view fields per section, 5 sections per animal, and 6–10 mice per experimental group, unless otherwise specified in the figures and legends.
Mean Vascular Density and Mean Vessel/Lumen Area
The mean vascular density was determined as the number of CD31-positive staining tumor samples per 40× field. For OrKPC and KPC GEM tumor samples, the mean vessel/lumen area was a measurement of CD31-positive stained areas using ImageJ software. Three view fields per section, 5 sections per tumor, were quantified as described in our previous report.
Determination of dFdCTP, dFdU, and dFdC Concentrations in Tumors by High-Performance Liquid Chromatography/Mass Spectrometry
Tissues from treated mice were dissected rapidly and snap-frozen in liquid nitrogen. The specimens were ground in liquid nitrogen, suspended in 0.4 N perchloric acid, and sonicated in an ice bath. Precipitates were removed by centrifugation, the pellet was washed with perchloric acid, and the supernatants were combined. After neutralization with potassium hydroxide and removal of KClO4 by centrifugation, a portion of the supernatant was analyzed for dFdCTP, dFdU, and dFdC in the samples by high-performance liquid chromatography, as described in previous studies. High-performance liquid chromatography analyses were performed using an Agilent Technologies (Santa Clara, CA) UHPLC system with a Zobax column. The mobile phase was a mixture of acetonitrile (A) and 0.1% formic acid in water (B) with a gradient elution. The flow rate was 0.6 mL/min. Mass spectrometric analysis was performed on a 6545QTOF mass spectrometer equipped with an electrospray ionization source in positive mode. During all the runs, the Quadrupole Time-of-Flight was calibrated by 2 reference masses (121.0508 and 922.0097 daltons) flowing at a continuous flow rate of 100 μL/min. Before analysis, the time of flight/mass spectrometry was calibrated using a reference solution consisting of masses (121.0508, 149.0233, 322.0481, 922.0097, 1221.9906, and 1521.9714 daltons) with a resolution greater than 10,000. For gemcitabine and dFdU, linearity was established in aqueous solution and saline. The method developed was sensitive and specific with no interference from the matrix at the retention of analytes or internal standard with an lower limit of quantitation of 7.81 nmol/L for both analytes. Phenacetin (500 ng/mL) was used as an internal standard. All samples were analyzed with calibration curve standards spanning a range of 7.81 to 1000 nmol/L. The amount of gemcitabine triphosphate was normalized to the adenosine triphosphate level determined in the same sample.
Statistical Calculations
Statistical analyses were performed using GraphPad Prism 6.0 software (Graphpad Holdings, LLC, La Jolla, CA). Kaplan–Meier survival curves were calculated using the survival time for each mouse from all treatment groups. Statistical analyses in the survival experiments were performed by log-rank (Mantel–Cox) test. All in vitro experiments were performed at least 5 times. For tumor burden analyses, image quantifications, and other analyses, statistical significance was assayed by unpaired Student t test. Box plots show ranges, medians, and quartiles.
Acknowledgments
The authors thank Bassel El-Rayes, Christine Alewine, Gregory Lesinski, David Tuveson, Robert B. Diasio, Thomas M. Roberts, and Liangwei Li for the useful suggestions and comments on the manuscript. The authors thank Mukkavilli Rao for help in quantification of gemcitabine and its metabolites. The authors are grateful to Chengliu Jin and Qian Liu for their help in GEMKPC mice breeding.
Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy.
Conflicts of interest These authors disclose the following: Zhi-Ren Liu holds shares in ProDa BioTech LLC, which licensed the rights to commercialize ProAgio; and Sun Li holds shares in Amoytop Biotech Co, Ltd, which licensed the rights to commercialize ProAgio in China. The remaining authors disclose no conflicts.
Funding This work is supported in part by research grants from the National Institutes of Health ( CA175112 , CA118113 , CA178730 , and CA217482 ) and the Georgia Cancer Coalition (Z.-R.L.); and by a Molecular Basis of Disease fellowship, Georgia State University (R.C.T. and M.S.).
30128-4&id=fx1.jpg){kind=link}
30128-4&id=gr1.jpg){kind=link}
30128-4&id=gr2.jpg){kind=link}
30128-4&id=gr3.jpg){kind=link}
30128-4&id=gr4.jpg){kind=link}
30128-4&id=gr5.jpg){kind=link}
30128-4&id=gr6.jpg){kind=link}
30128-4&id=gr7.jpg){kind=link}
30128-4&id=gr8.jpg){kind=link}
30128-4&id=gr9.jpg){kind=link}
30128-4&id=gr10.jpg){kind=link}